December 15, 2021 -- CellCarta announced the acquisition of Biogazelle to strengthen its genomic capabilities and expand into digital polymerase chain reaction (dPCR) services.
Biogazelle is a Ghent University spinoff, with the financial support of BNP Paribas Fortis and investment from Qbic, PMV, and the Fournier-Majoie Foundation. Biogazelle also provides RNA sequencing workflows on clinical samples such as liquid biopsies and formalin-fixed paraffin-embedded tissues.
Biogazelle will become CellCarta's Center of Excellence for the development of complex genomic biomarker assays. The acquisition allows CellCarta to expand its offering to clients in fields with high demand in genomic analysis, such as immuno-oncology and cell and gene therapy, the firm said.
CellCarta provides specialized precision medicine laboratory services to the biopharmaceutical industry. The company operates globally with 10 facilities.
No financial agreements were disclosed.
Copyright © 2021 scienceboard.net